Wednesday, Jun 20 2018 | Time 06:59 Hrs(IST)
image
image
  • US quits UN human rights body, citing bias vs Israel, alarming critics
  • UN rights boss says US should be stepping up, not retreating
  • US withdraws from U N Human Rights Council -US Ambassador Haley
  • FIFA World cup: Russia beats Egypt by 3-1
  • Russia on brink of knockout stage after win over Egypt
  • England hit record 481 in ODI thrashing of Australia
  • Soccer-Brazil winless but not worrying yet, says Coutinho
Science Technology Share

Circassia gives up on allergy after house dust mite study fails"

Circassia gives up on allergy after house dust mite study fails"

LONDON, Apr 18 (Reuters) Britain's Circassia Pharmaceuticals is throwing in the towel on allergy investment after a second high-profile clinical trial flop, focusing instead on building a broader respiratory business.The failure of the company's immunotherapy to perform better than placebo in fighting dust mite allergy in a Phase IIb test follows similar negative results in a Phase III trial against cat allergy last year. The company's stock lost two-third's of its value in a single session on the June 2016 cat results, which many investors feared undermined the allergy thesis, and the reaction on Tuesday was more muted, with shares losing around 3 percent. In both cases, the company said, the immunotherapy failed because of a marked placebo effect among patients not on therapy. The top shareholders in Circassia, which listed on the London stock market in March 2014 in Britain's largest biotech flotation for decades, are Invesco and Neil Woodford's investment management company, both big backers of UK science. Woodford suffered another setback earlier this month when Allied Minds, which commercialises ideas from universities, announced a large writedown. Circassia Chief Executive Steve Harris said he was "naturally disappointed" by the dust mite study failure. "We remain convinced that the technology has biologic activity, but we also believe the difficulty in overcoming the placebo effect using the field study designs required by regulators represents a significant hurdle, and consequently we will make no further investment in our allergy portfolio," he said. Instead, Circassia will concentrate on its wider respiratory business, in particular a new U.S. commercial collaboration with AstraZeneca. Circassia last month secured U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease for up to $230 million. REUTERS RJ

More News
India, the cardiac capital

India, the cardiac capital

14 Jun 2018 | 5:15 PM

By Sanya Pandey
New Delhi, June 14 (UNI) India houses around three crore heart patients and two lakh surgeries are performed in it every year.

 Sharesee more..
Congenital anomalies important causes of infant and childhood deaths

Congenital anomalies important causes of infant and childhood deaths

13 Jun 2018 | 12:53 PM

Kolkata, Jun 13 (UNI) Congenital anomalies are important causes of infant and childhood
deaths, chronic illness and disability.

 Sharesee more..
World Blood Donor Day celebrated on Jun 14 to aware people of Human Blood

World Blood Donor Day celebrated on Jun 14 to aware people of Human Blood

12 Jun 2018 | 1:26 PM

Kolkata, Jun 12 (UNI) World Blood Donor Day is celebrated every year on June 14 around the world to make people aware of the Human Blood and its requirement to save lives.

 Sharesee more..
Saliva test can identify men more likely to get prostrate cancer

Saliva test can identify men more likely to get prostrate cancer

12 Jun 2018 | 11:32 AM

London, Jun 12 (UNI) After UK researchers tracked down a host of genetic changes that make the prostate cancer up to four times more likely, soon a saliva swab will help identify the men most at risk of the disease.

 Sharesee more..
Good quality care key to keeping mothers and babies alive and well: WHO

Good quality care key to keeping mothers and babies alive and well: WHO

11 Jun 2018 | 2:57 PM

Kolkata, Jun 11 (UNI) There is increasing global awareness that good quality care is key to keeping mothers and babies alive and well.

 Sharesee more..
image